Copyright
©The Author(s) 2017.
World J Gastroenterol. Jul 21, 2017; 23(27): 4958-4967
Published online Jul 21, 2017. doi: 10.3748/wjg.v23.i27.4958
Published online Jul 21, 2017. doi: 10.3748/wjg.v23.i27.4958
Table 4 Single nucleotide polymorphism genotypes according to anti-tumor necrosis factor treatment response
| SNP | Genotype | Anti-TNF treatment response | P value1 | |
| Non-responders | Responders | |||
| ATG16L1 rs10210302 | CC | 5 (25.0) | 20 (20.2) | NS |
| TC | 9 (45.0) | 48 (48.5) | ||
| TT | 6 (30.0) | 31 (31.3) | ||
| ATG16L1 rs2241880 | AA | 5 (23.8) | 22 (22.2) | NS |
| GA | 10 (47.6) | 47 (47.5) | ||
| GG | 6 (28.6) | 30 (30.3) | ||
| FAS Ligand rs763110 | CC | 12 (60.0) | 30 (31.6) | 0.042 |
| TC | 5 (25.0) | 49 (51.6) | ||
| TT | 3 (15.0) | 16 (16.8) | ||
| FAS Ligand rs763110 (grouped) | CC | 12 (60.0) | 30 (31.6) | 0.016 OR = 3.23, 95%CI: 1.20-8.78 |
| TC + TT | 8 (40.0) | 65 (68.4) | ||
| IBD5 rs2522057 | CC | 6 (28.6) | 29 (29.3) | NS |
| GC | 9 (42.9) | 40 (40.4) | ||
| GG | 6 (28.6) | 30 (30.3) | ||
| FCGR 3A rs396991 | AA | 11 (52.4) | 59 (59.6) | NS |
| AC | 6 (28.6) | 27 (27.3) | ||
| CC | 4 (19.0) | 13 (13.1) | ||
| TNF gene (-308) rs1800629 | AA | 2 (10.0) | 2 (2.0) | 0.088 |
| GA | 7 (35.0) | 24 (24.2) | ||
| GG | 11 (55.0) | 73 (73.7) | ||
| TNF gene (-308) rs1800629 (grouped) | AA + GA | 9 (45.0) | 26 (26.3) | 0.093 OR = 2.29, 95%CI: 0.85-6.17 |
| GG | 11 (55.0) | 73 (73.7) | ||
| TNF gene (-238) rs361525 | AA | 0 (0.0) | 2 (2.0) | NS |
| GA | 2 (10.0) | 13 (13.0) | ||
| GG | 18 (90.0) | 85 (85.0) | ||
- Citation: Netz U, Carter JV, Eichenberger MR, Dryden GW, Pan J, Rai SN, Galandiuk S. Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn’s disease. World J Gastroenterol 2017; 23(27): 4958-4967
- URL: https://www.wjgnet.com/1007-9327/full/v23/i27/4958.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i27.4958